Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 14

1.

Association of programmed death ligand-1 (PD-L1) expression with treatment outcomes in patients with BRAF mutation-positive melanoma treated with vemurafenib or cobimetinib combined with vemurafenib.

Wongchenko MJ, Ribas A, Dréno B, Ascierto PA, McArthur GA, Gallo JD, Rooney IA, Hsu J, Koeppen H, Yan Y, Larkin J.

Pigment Cell Melanoma Res. 2018 Jul;31(4):516-522. doi: 10.1111/pcmr.12670. Epub 2017 Dec 10.

PMID:
29156488
2.

SGX523 is an exquisitely selective, ATP-competitive inhibitor of the MET receptor tyrosine kinase with antitumor activity in vivo.

Buchanan SG, Hendle J, Lee PS, Smith CR, Bounaud PY, Jessen KA, Tang CM, Huser NH, Felce JD, Froning KJ, Peterman MC, Aubol BE, Gessert SF, Sauder JM, Schwinn KD, Russell M, Rooney IA, Adams J, Leon BC, Do TH, Blaney JM, Sprengeler PA, Thompson DA, Smyth L, Pelletier LA, Atwell S, Holme K, Wasserman SR, Emtage S, Burley SK, Reich SH.

Mol Cancer Ther. 2009 Dec;8(12):3181-90. doi: 10.1158/1535-7163.MCT-09-0477.

3.

Methods of study of tumor necrosis factor-related ligands in apoptosis.

Rooney IA, Benedict CA, Norris PS, Ware CF.

Methods Cell Biol. 2001;66:499-526. No abstract available.

PMID:
11396019
4.

The lymphotoxin-beta receptor is necessary and sufficient for LIGHT-mediated apoptosis of tumor cells.

Rooney IA, Butrovich KD, Glass AA, Borboroglu S, Benedict CA, Whitbeck JC, Cohen GH, Eisenberg RJ, Ware CF.

J Biol Chem. 2000 May 12;275(19):14307-15.

6.

Control of the complement system.

Liszewski MK, Farries TC, Lublin DM, Rooney IA, Atkinson JP.

Adv Immunol. 1996;61:201-83. Review.

PMID:
8834497
7.

Role of virion-associated glycosylphosphatidylinositol-linked proteins CD55 and CD59 in complement resistance of cell line-derived and primary isolates of HIV-1.

Saifuddin M, Parker CJ, Peeples ME, Gorny MK, Zolla-Pazner S, Ghassemi M, Rooney IA, Atkinson JP, Spear GT.

J Exp Med. 1995 Aug 1;182(2):501-9.

9.

Complement in human reproduction: activation and control.

Rooney IA, Oglesby TJ, Atkinson JP.

Immunol Res. 1993;12(3):276-94. Review.

PMID:
8288946
12.

The complement-inhibiting protein, protectin (CD59 antigen), is present and functionally active on glomerular epithelial cells.

Rooney IA, Davies A, Griffiths D, Williams JD, Davies M, Meri S, Lachmann PJ, Morgan BP.

Clin Exp Immunol. 1991 Feb;83(2):251-6.

14.

Non-lethal doses of antibody and complement stimulate release of prostaglandin E2 from human amniotic cells in vitro.

Rooney IA, Morgan BP.

Biochem Soc Trans. 1990 Aug;18(4):617. No abstract available.

PMID:
2276469

Supplemental Content

Loading ...
Support Center